The COVID-19 pandemic has—without warning—turned clinical operations on its head, forcing the clinical research community to re-evaluate how to manage clinical trials. In an instant, physical access to patients across the globe ceased to be an option, having a significant impact on data collection and patient monitoring.
In this new environment that is forcing change, many organizations have accelerated their plans to shift to a decentralized clinical trial model. With this transition comes many benefits and challenges, and begs the question: are clinical development organizations prepared for this paradigm shift?
To explore the impact of the current environment on clinical trial management, Informa Pharma Intelligence and Oracle Health Sciences surveyed professionals involved in clinical trials at biopharmaceutical companies, medical device companies, and contract research organizations (CROs) based around the world.
The research results provide valuable insight into how the COVID-19 pandemic is changing the way clinical trials are being conducted, and identifies the key challenges and opportunities surrounding these changes.